SlatopolskyE., CaglerS., GradowskyL., CanterburyJ., ReiseE., BaikerN.S.The prevention of secondary hyperparathiroidism experimental chronic renal disease using proportional reduction of dietary phosphorus intake.Kidney Int1972; 2: 147–52.
2.
AlfreyA.C., Le GendreG.R., KaehnyW.D.The dialysis encephalopathy syndrome: possible aluminium intoxication.New Eng J Med1976; 294: 184–8.
3.
ClarksonE.M., Mc DonaldS.J., deWardenerH.E.The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure.Clin Sci1966; 30: 425–38.
4.
SperchneiderH., GuntherK., MarzollI., KirchnerE., SteinG.Calcium carbonate (CaCO3): an efficient and safe phosphate binder in haemodialysis patients? A 3-year study.Nephrol Dial Trap1993; 8: 530–4.
5.
SchaeferK.Alternative phosphate binders: an update.Nephrol Dial Trap1993; 1: 35–9.
6.
SheikhM.S., MaguireJ.A., EmmettM.Reduction of dietary phosphorus absorption by phosphorus binders: a theorical, in vitro and in vivo study.J Clin Invest1988; 83: 66–73.
7.
MaiH.L., EmmettM., SheikhM.S.Calcium acetate, an effective phosphorus binder in patients with renal failure.Kidney Int1989; 36: 690–6.
8.
CappelliG., LealeN., RattoG., BoffanoP., CaroleoM.G., MalaspinaM.Il calcio acetato nel trattamento dell'iperfosforemia in dialisi.Atti del Congresso di Bardonecchia.Milano: Wichtig Editore1993 (in stampa).
9.
HessB., BinswangerU.Long-term administration of calcium acetate efficiently controls severe hyperphosphataemia in haemodialysis Patients.Nephrol Dial Trap1990; 5: 630–2.
10.
AllariaP., CantùP., LimidoA.L'impiego del calcio acetato nel controllo farmacologico dell'iperfosforemia del paziente uremico.Giorn It Nefrol1991; 6: 317.
